Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 3/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11064389 | 0.80 | TLR8 (0.37) | TLR8CYP3A4CYP2D6 | |
| SCHEMBL22613548 | 0.78 | ALOX15 (0.33) | MEN1KMT2ATLR8 | |
| SCHEMBL5719359 | 0.77 | TLR8 (0.32) | TLR8 | |
| SCHEMBL15921771 | 0.75 | TLR8 (0.31) | TLR8 | |
| SCHEMBL1935159 | 0.74 | LOX (0.44) | LOXLOXL2MEN1PABPC1KMT2A | |
| SCHEMBL29851553 | 0.74 | LOX (0.44) | LOXLOXL2MEN1PABPC1KMT2A | |
| SCHEMBL23162741 | 0.73 | — | — | |
| SCHEMBL23162752 | 0.73 | PTGS2 (0.34) | LOXLOXL2GRM5TLR8 | |
| SCHEMBL109668 | 0.73 | CYP2D6 (0.34) | KMT2ACYP3A4CYP2D6 | |
| SCHEMBL29779695 | 0.72 | PDE10A (0.35) | TXNRD1GSRPDE10AGRM5TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2024-09-10 | — | — | US | disclosed |
| CN-117659010-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4038064-B1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2024-02-21 | — | — | EP | disclosed |
| CN-111867581-B | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-29 | — | — | US | disclosed |
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| EP-4038064-A1 | N-SUBSTUTUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| EP-4038068-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021064571-A1 | N-SUBSTITUTED-4-OXO-3,4-DIHYDROPYRIDO[2,3-D]PYRIMIDIN-2-YL DERIVATIVES AS INHIBITORS OF THE HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2021-04-08 | — | — | WO | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3746071-A1 | GCN2 INHIBITORS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| CN-111867581-A | GCN2 inhibitors and uses thereof | 默克专利股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| WO-2019148136-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | WO | disclosed |
| WO-2014022377-A1 | MEMBRANES AND COATINGS MADE FROM MIXTURES INCLUDING IONIC LIQUIDS HAVING SILICON-BONDED HYDROLYZABLE GROUPS | DOW CORNING CORPORATION (US) | 2014-02-06 | — | — | WO | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008076046-A1 | NOVEL 2-AMINO-5, 5-DIARYL-IMIDAZOL-4-ONES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389007-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | TAAR1 4802/4885MTNR1A 4782/4885MTNR1B 4735/4885 |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | TAAR1 3484/4885MTNR1A 3347/4885MTNR1B 2060/4885 |
| US-12084438-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | TAAR1 4463/4885MTNR1A 3087/4885MTNR1B 1621/4885 |
| US-20220409619-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | TAAR1 4802/4885MTNR1A 4782/4885MTNR1B 4735/4885 |
| US-20250059190-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TAAR1 4463/4885MTNR1A 3087/4885MTNR1B 1621/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TAAR1 4463/4885MTNR1A 3087/4885MTNR1B 1621/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | TAAR1 4463/4885MTNR1A 3087/4885MTNR1B 1621/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | TAAR1 4463/4885MTNR1A 3087/4885MTNR1B 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.